We will be contrasting the differences between Intec Pharma Ltd. (NASDAQ:NTEC) and TCR2 Therapeutics Inc. (NASDAQ:TCRR) as far as risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.
In table 1 we can see Intec Pharma Ltd. and TCR2 Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 has Intec Pharma Ltd. and TCR2 Therapeutics Inc.’s return on equity, return on assets and net margins.
The next table highlights the given recommendations and ratings for Intec Pharma Ltd. and TCR2 Therapeutics Inc.
Meanwhile, TCR2 Therapeutics Inc.’s average target price is $28, while its potential upside is 91.91%.
Insider and Institutional Ownership
The shares of both Intec Pharma Ltd. and TCR2 Therapeutics Inc. are owned by institutional investors